Cannabis includes hundreds of different chemical, some of which have promising medicinal value. What does it take to get more cannabis based medications that are FDA approved?
Jacquelyn L. Bainbridge, BSPharm , PharmD, , FCCP, MSCS, FAES
Jacquelyn L. Bainbridge, BSPharm, PharmD, FCCP, MSCS, FAES, is a Professor at the University of Colorado Anschutz Medical Campus, where she holds joint appointments in the Skaggs School of Pharmacy and Pharmaceutical Sciences, Department of Clinical Pharmacy, and the Department of Neurology in the School of Medicine. Dr Bainbridge received her doctorate in pharmacy from the University of Colorado in Denver, where she subsequently completed a specialty residency in neurology.
Dr Bainbridge is a Multiple Sclerosis Certified Specialist (MSCS) who is actively involved in clinical research in many areas of neurology, including multiple sclerosis (MS), epilepsy, geriatrics, Parkinson’s disease (PD), back pain, cannabis, and psilocybin. Currently, she is working on 3 clinical trials investigating cannabis for the treatment of back pain, PD and autism, sponsored by the Colorado Department of Public Health and Environment (CDPHE), and 1 synthetic cannabidiol (CBD) study involving patients with Fragile X syndrome. Dr. Bainbridge is involved in 1 additional clinical trial sponsored by the CDPHE, for back pain in patients not on opiates or on opiates, with a dose reduction using cannabis (CBD and delta 9 tetrahydrocannabinol (THC)). Dr. Bainbridge is also involved in 2 psilocybin trials 1 involving cancer patients and one involving severe depression. Additionally, Dr. Bainbridge is reporting on post-surgical cancer patients and their endocannabinol response whether they are a cannabis user or not. Dr Bainbridge continues to study the safety and efficacy of antiseizure medications (ASMs) in older adults. She was previously an investigator for several National Institutes of Health (NIH)-funded trials researching drugs that may be neuroprotective in PD. Dr. Bainbridge has completed 1 clinical trial using a synthetic CBD product in patients with scleroderma. She has published several articles in professional journals, including Epilepsia, Pharmacotherapy, The International Journal of Multiple Sclerosis Care, and the American Journal of Health-System Pharmacy. She has reviewed and written several book chapters on MS, epilepsy, migraine, chronic pain, women’s issues, pharmacokinetics, and the practice of pharmacy. Dr Bainbridge is a frequent lecturer on topics of neurologic and pharmacologic interest, including MS, chronic pain disorders, epilepsy, migraine, movement disorders, neuroprotection, restless legs syndrome (RLS), Huntington’s disease and the administration of cannabis for therapeutic intent.
Dr Bainbridge is a member of numerous professional organizations, including The Consortium of Multiple Sclerosis Centers (CMSC), The National Multiple Sclerosis Society (NMSS) Epilepsy Foundation of Colorado, the American Academy of Neurology (AAN), the American Epilepsy Society(AES), Epilepsy Foundation of America (EFA), American College of Clinical Pharmacy (ACCP), American Association of Colleges of Pharmacy (AACP), Colorado Pharmacists Society (CPS), and American Society of Health-System Pharmacists (ASHP). She is the past president of the board of directors for The Restless Legs Syndrome Foundation (RLSF) and The Epilepsy Foundation of Colorado (EFC). Dr. Bainbridge is currently on the Board of Governors for The Consortium of Multiple Sclerosis Centers (CMSC), and on the Board of Directors for The Epilepsy Foundation of Colorado and Wyoming Professional Advisory Board and The American Lung Association (ALA). Dr. Bainbridge has been elected as a Fellow of the American College of Clinical Pharmacy (FCCP), Fellow of the American Epilepsy Society (FAES) and has won several student preceptor and teaching class awards. Dr. Bainbridge has been asked to address the United Nations in Vienna on the safe practice of cannabis use in March of 2023.
